NattoPharma
News and Media
Event calendar
-
SupplySide Market place
New York, USA
-
Vitafoods Europe
Geneva, Switzerland
Article on the Effect of MenaQ7 Natural Vitamin K2 published by the American Journal of Kidney Disease
In a press release on December 10, 2009 Nattopharma announced the first use of MenaQ7, the natural vitamin K2, as an intervention in a placebo controlled clinical trial on dialysis patients. The aim of the study was to assess the effects of natural vitamin K2 on vascular health parameters in a patient group that has a very high degree of risk for cardiovascular disease.
The authors of the article state that:
The study confirms that most hemodialysis patients have a functional vitamin K deficiency. More importantly, it is the first study showing that inactive MGP levels can be decreased markedly by daily vitamin K2 supplementation. Our study provides the rationale for intervention trials aimed at decreasing vascular calcification in hemodialysis patients by vitamin K supplementation
For more information, please contact VP R&D Dan Edwall
For the Press
Press inquire:
Erik Tjørstad,
CFO/ IR Contact
erik@nattopharma.com
(+ 47) 916 36 395
Camilla Lindberg,
Marketing Manager
camilla@nattopharma.com
(+47) 909 54 793
Created by:
